Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
E. Kon, Y. Levy, U. Elia, H. Cohen, I. Halevy, M. Aftalion, A. Ezra, E. Bar-Haim, G. S. Naidu, Y. Diesendruck, S. Rotem, N. Ad-El, M. Goldsmith, E. Mamroud, D. Peer, O. Cohen
This study develops an mRNA-LNP vaccine against Yersinia pestis, showing it provides full protection against infection in animals.
bioRxiv · Aug 7, 2022 · PreprintMicrobiology
H. Cohen, S. Rotem, U. Elia, G. Bilinsky, I. Levy, T. Chitlaru, E. Bar-Haim
The study assesses T cell responses to the ancestral and Omicron SARS-CoV-2 spike proteins post-BNT162b2 vaccination, finding comparable reactivity and a dominant Th1 response.
bioRxiv · Jan 19, 2022Immunology
M. Israeli, Y. Finkel, Y. Yahalom-Rone, N. Paran, T. Chitlaru, O. Israeli, I. Cohen-Gihon, M. Aftalion, R. Falach, U. Elia, I. Nemet, L. Kliker, M. Mandelboim, A. Beth-Din, T. Israely, , A. Bercovich-Kinori
This study uses CRISPR screens to identify host factors critical for SARS-CoV-2 infection, finding GATA6 as a key modulator of ACE2 expression and viral entry.
bioRxiv · Jul 19, 2021 · PreprintMicrobiology
N. Madar-Balakirski, A. Rosner, S. Melamed, B. Politi, M. Steiner, H. Tamir, Y. Yahalom Ronen, E. Bar-David, A. Ben-Shmuel, A. Sittner, I. Glinert, S. Weiss, E. Bar-Haim, H. Cohen, U. Elia, , H. Marcus
This study evaluates the safety, immunogenicity, and efficacy of an rVSV-ΔG-SARS-CoV-2-S vaccine in multiple animal species, finding no adverse effects and a robust immune response.
bioRxiv · Jul 6, 2021Pharmacology & Toxicology
U. Elia, S. Rotem, E. Bar-Haim, S. Ramishetti, G. S. Naidu, D. Gur, M. Aftalion, M. Israeli, A. Bercovich-Kinori, R. Alcalay, E. Makdasi, T. Chitlaru, R. Rosenfeld, T. Israely, S. Melamed, , O. Cohen
This study evaluates an mRNA vaccine against SARS-CoV-2 in hACE2 transgenic mice, showing 70% protection against a lethal infection.
bioRxiv · Mar 29, 2021Microbiology
U. Elia, R. Srinivas, N. Dammes, E. Bar-Haim, G. S. Naidu, E. Makdasi, O. Cohen, D. Peer
This study designs an mRNA vaccine targeting SARS-CoV-2 RBD using novel ionizable lipids, showing strong immune responses in mice.
bioRxiv · Oct 15, 2020Immunology